Suppr超能文献

侵犯纵隔的III期肺癌的外科治疗结果

Results of surgical treatment of stage III lung cancer invading the mediastinum.

作者信息

Burt M E, Pomerantz A H, Bains M S, McCormack P M, Kaiser L R, Hilaris B S, Martini N

出版信息

Surg Clin North Am. 1987 Oct;67(5):987-1000. doi: 10.1016/s0039-6109(16)44337-9.

Abstract

From 1974 to 1984, 225 patients underwent thoracotomy at Memorial Sloan-Kettering Cancer Center for primary non-small cell lung cancer invading only the mediastinum (T3). The perioperative mortality was 2.7 per cent, and the nonfatal complication rate 13 per cent. Forty-nine patients underwent complete resection of all intrathoracic disease, with a median survival of 17 months, 3-year survival of 21 per cent, and 5-year survival of 9 per cent. Thirty-three patients underwent pulmonary resection with simultaneous iodine-125 interstitial implantation or iridium-192 delayed afterloading to areas of unresectable primary or nodal disease, with a median survival of 12 months, 3-year survival of 22 per cent, and 5-year survival of 22 per cent. One hundred and one patients underwent interstitial implantation without resection, with a median survival of 11 months, 3-year survival of 9 per cent, and no 5-year survivors. Forty-two patients had incomplete resection without intraoperative radiation therapy and fared no better than a cohort group of 44 unoperated patients with clinical evidence of mediastinal invasion--both groups had a median survival of 8 months and no 3-year survivors. An aggressive surgical approach with pulmonary resection and/or brachytherapy appears to offer some survival advantage to this group of patients. In particular, 5-year survival rates ranging from 7 to 15 per cent were observed in subsets of intraoperatively treated patients with invasion of pulmonary vein, phrenic nerve, esophagus, or pericardium and in those with clinically occult T3 disease.

摘要

1974年至1984年期间,225例患者在纪念斯隆凯特琳癌症中心接受了开胸手术,治疗仅侵犯纵隔的原发性非小细胞肺癌(T3)。围手术期死亡率为2.7%,非致命并发症发生率为13%。49例患者接受了所有胸内疾病的完全切除,中位生存期为17个月,3年生存率为21%,5年生存率为9%。33例患者接受了肺切除,同时对不可切除的原发性或淋巴结疾病区域进行碘-125间质植入或铱-192后装治疗,中位生存期为12个月,3年生存率为22%,5年生存率为22%。101例患者接受了间质植入但未进行切除,中位生存期为11个月,3年生存率为9%,无5年生存者。42例患者未进行术中放疗的不完全切除,其预后并不优于一组有纵隔侵犯临床证据的44例未手术患者——两组的中位生存期均为8个月,无3年生存者。积极的手术方法,包括肺切除和/或近距离放射治疗,似乎为这组患者提供了一些生存优势。特别是,在术中接受治疗的侵犯肺静脉、膈神经、食管或心包的患者亚组以及有临床隐匿性T3疾病的患者中,观察到5年生存率在7%至15%之间。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验